Safety, tolerability and CNS effects after single and multiple doses of β-agonists in healthy volunteers and patients with Parkinson’s disease
Objective: This study aimed to assess the effects of β-agonists on central nervous system (CNS) functioning in healthy volunteers and patients with Parkinson’s disease. Background:…Effects of Once-Daily Opicapone 50 mg on the Pharmacokinetics of Levodopa Administered as Carbidopa/Levodopa Extended-Release Capsules: An Open-Label Phase 1 Study
Objective: To assess the effects of opicapone 50 mg on the pharmacokinetics (PK) of levodopa (LD) and its metabolite, 3-O-methyldopa (3-OMD), when administered with oral…Community-Based Multidisciplinary Program for People with Parkinson Disease: A 2-year comparison
Objective: The current study reports outcomes from a 2 year-long community-based multidisciplinary program for individuals with Parkinson disease (PD) and their families based in Oklahoma…Local Field Potentials (LFP) used to guide treatment of biphasic dyskinesias in a patient with Parkinson’s Disease (PD)
Objective: To identify, characterize and treat dyskinesias and off time in a patient with PD via the use of gamma and beta peak LFP using…Transcranial Magnetic Stimulation in Parkinsonism. Tremor and Biomechanics Evaluation
Objective: The aim of our study was to reveal the relationship between motor and muscle activity шт terms of plantar pressure distribution PPD) in Parkinson's…Challenges in Implementing Relevant Exercise Interventions in Mouse Models of Parkinson’s Disease
Objective: To determine the suitability of a motorized wheel as a forced exercise modality that does not rely on aversive stimuli for use in Parkinson’s…Emotional processing and response times in Parkinson’s disease
Objective: The aim of this behavioural study was to test whether motor response is mainly driven by the emotional content of a picture or if…Dissociable contribution of serum NfL and p-tau181 to cognitive impairment and mild cognitive impairment in Parkinson’s disease.
Objective: To analyze the contribution of serum NfL and p-tau181 levels to cognitive impairment and mild cognitive impairment (PD-MCI) in non-demented PD patients. Background: Autopsy…The study of genetic factors in motor levodopa-induced complications development in Russian patients with Parkinson’s disease
Objective: The aim of our study is to search for genetic risk factors for the development of motor side effects of dopaminergic therapy, such as…Building a Global Parkinson’s Genetics Program (GP2): Clinical Cohorts Integration Working Group
Objective: To recruit Parkinson's Disease (PD) cohorts across the world for the global Parkinson's Genetics Program (GP2, http://gp2.org/), harmonise clinical data across cohorts for joint…
- « Previous Page
- 1
- …
- 406
- 407
- 408
- 409
- 410
- …
- 436
- Next Page »